Dyax (DYAX) Higher After Competing Drug Fails to Hit Endpoint
More News related to DYAX
- Dyax Announces Underwriter's Exercise of Over-allotment Option
- Dyax Corp. (DYAX) Sells 7.4M Shares at $2.02
- Dyax Announces $15 Million Financing
- Wedbush Morgan Maintains a 'Buy' on Dyax (DYAX); Comments on FDA Action
- Dyax (DYAX) Said Study Shows DX-88 Provides Rapid and Sustained Relief for Hereditary Angioedema
Dyax Corp. (Nasdaq: DYAX) is 15% higher in after-hours action. According to a representative from the company, a competing drug for hereditary angioedema (HAE) from Jerini (www.jerini.com) did not meet its primary endpoint in one of two pivotal Phase III trials (FAST-1)
Dyax's lead product candidate is DX-88, a recombinant small protein that is currently in clinical trials for its therapeutic potential in two separate indications. In its joint venture with Genzyme Corporation, Dyax has successfully completed three Phase II trials of DX-88 for the treatment of hereditary angioedema (HAE). A Phase III trial is ongoing.
Related Categories
FDAHot List
Stocks Mentioned
+0.15Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
